Delcath Systems Inc
NASDAQ:DCTH

Watchlist Manager
Delcath Systems Inc Logo
Delcath Systems Inc
NASDAQ:DCTH
Watchlist
Price: 10.77 USD 2.57% Market Closed
Market Cap: 301.6m USD
Have any thoughts about
Delcath Systems Inc?
Write Note

Intrinsic Value

The intrinsic value of one DCTH stock under the Base Case scenario is 17.26 USD. Compared to the current market price of 10.77 USD, Delcath Systems Inc is Undervalued by 38%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

DCTH Intrinsic Value
17.26 USD
Undervaluation 38%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Delcath Systems Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for DCTH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about DCTH?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Delcath Systems Inc

Provide an overview of the primary business activities
of Delcath Systems Inc.

What unique competitive advantages
does Delcath Systems Inc hold over its rivals?

What risks and challenges
does Delcath Systems Inc face in the near future?

Has there been any significant insider trading activity
in Delcath Systems Inc recently?

Summarize the latest earnings call
of Delcath Systems Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Delcath Systems Inc.

Provide P/S
for Delcath Systems Inc.

Provide P/E
for Delcath Systems Inc.

Provide P/OCF
for Delcath Systems Inc.

Provide P/FCFE
for Delcath Systems Inc.

Provide P/B
for Delcath Systems Inc.

Provide EV/S
for Delcath Systems Inc.

Provide EV/GP
for Delcath Systems Inc.

Provide EV/EBITDA
for Delcath Systems Inc.

Provide EV/EBIT
for Delcath Systems Inc.

Provide EV/OCF
for Delcath Systems Inc.

Provide EV/FCFF
for Delcath Systems Inc.

Provide EV/IC
for Delcath Systems Inc.

Show me price targets
for Delcath Systems Inc made by professional analysts.

What are the Revenue projections
for Delcath Systems Inc?

How accurate were the past Revenue estimates
for Delcath Systems Inc?

What are the Net Income projections
for Delcath Systems Inc?

How accurate were the past Net Income estimates
for Delcath Systems Inc?

What are the EPS projections
for Delcath Systems Inc?

How accurate were the past EPS estimates
for Delcath Systems Inc?

What are the EBIT projections
for Delcath Systems Inc?

How accurate were the past EBIT estimates
for Delcath Systems Inc?

Compare the revenue forecasts
for Delcath Systems Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Delcath Systems Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Delcath Systems Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Delcath Systems Inc compared to its peers.

Compare the P/E ratios
of Delcath Systems Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Delcath Systems Inc with its peers.

Analyze the financial leverage
of Delcath Systems Inc compared to its main competitors.

Show all profitability ratios
for Delcath Systems Inc.

Provide ROE
for Delcath Systems Inc.

Provide ROA
for Delcath Systems Inc.

Provide ROIC
for Delcath Systems Inc.

Provide ROCE
for Delcath Systems Inc.

Provide Gross Margin
for Delcath Systems Inc.

Provide Operating Margin
for Delcath Systems Inc.

Provide Net Margin
for Delcath Systems Inc.

Provide FCF Margin
for Delcath Systems Inc.

Show all solvency ratios
for Delcath Systems Inc.

Provide D/E Ratio
for Delcath Systems Inc.

Provide D/A Ratio
for Delcath Systems Inc.

Provide Interest Coverage Ratio
for Delcath Systems Inc.

Provide Altman Z-Score Ratio
for Delcath Systems Inc.

Provide Quick Ratio
for Delcath Systems Inc.

Provide Current Ratio
for Delcath Systems Inc.

Provide Cash Ratio
for Delcath Systems Inc.

What is the historical Revenue growth
over the last 5 years for Delcath Systems Inc?

What is the historical Net Income growth
over the last 5 years for Delcath Systems Inc?

What is the current Free Cash Flow
of Delcath Systems Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Delcath Systems Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Delcath Systems Inc

Current Assets 31.4m
Cash & Short-Term Investments 19.9m
Receivables 3.7m
Other Current Assets 7.7m
Non-Current Assets 2.5m
PP&E 2.5m
Current Liabilities 12.3m
Accounts Payable 3.3m
Accrued Liabilities 4.5m
Other Current Liabilities 4.5m
Non-Current Liabilities 17.4m
Other Non-Current Liabilities 17.4m
Efficiency

Earnings Waterfall
Delcath Systems Inc

Revenue
11.9m USD
Cost of Revenue
-2.7m USD
Gross Profit
9.2m USD
Operating Expenses
-45.2m USD
Operating Income
-36.1m USD
Other Expenses
-20.3m USD
Net Income
-56.3m USD

Free Cash Flow Analysis
Delcath Systems Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q2 2024, Delcath Systems reported $7.8 million in revenue, driven by $6.6 million from the U.S. HEPZATO sales and $1.2 million from European CHEMOSAT sales. The company ended the quarter with 8 active treatment centers, forecasting 20 centers by the end of 2024. The average treatment rate exceeded expectations at just under 2 per month per center. Achieving New Technology Add-on Payment (NTAP) status for HEPZATO, Delcath expects to reach $10 million in quarterly U.S. revenue by Q4 2024, triggering $25 million in cash proceeds and potentially achieving cash flow positivity by Q1 2025.

What is Earnings Call?
Fundamental Scores

DCTH Profitability Score
Profitability Due Diligence

Delcath Systems Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
31/100
Profitability
Score

Delcath Systems Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

DCTH Solvency Score
Solvency Due Diligence

Delcath Systems Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
39/100
Solvency
Score

Delcath Systems Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DCTH Price Targets Summary
Delcath Systems Inc

Wall Street analysts forecast DCTH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DCTH is 21.76 USD with a low forecast of 18.18 USD and a high forecast of 26.25 USD.

Lowest
Price Target
18.18 USD
69% Upside
Average
Price Target
21.76 USD
102% Upside
Highest
Price Target
26.25 USD
144% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for DCTH?

Click here to dive deeper.

Dividends

Delcath Systems Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for DCTH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

DCTH Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Delcath Systems Inc Logo
Delcath Systems Inc

Country

United States of America

Industry

Health Care

Market Cap

300.8m USD

Dividend Yield

0%

Description

Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 45 full-time employees. The company went IPO on 2000-10-19. The firm's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical device having the same device components as the HEZPATO KIT but without the melphalan hydrochloride, is designated as a Class III medical device, and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it is being used at various medical centers to treat a range of cancers of the liver. In the United States, HEPZATO KIT is considered a combination drug and device product. The firm's product administers concentrated regional chemotherapy to the liver.

Contact

NEW YORK
New York City
1633 Broadway Ste 22C
+12124892100.0
delcath.com

IPO

2000-10-19

Employees

45

Officers

CEO & Director
Mr. Gerard J. Michel MBA, MS
Senior VP of Finance and Principal Financial & Accounting Officer
Ms. Sandra Pennell
Chief Operating Officer
Dr. Martha S. Rook Ph.D.
General Counsel, Corporate Secretary & Chief Compliance Officer
Mr. David Hoffman
Senior Vice President of Clinical Operations & Medical Affairs
Dr. Johnny John M.D.
Chief Medical Officer
Dr. Vojislav Vukovic M.D., M.Sc., Ph.D.

See Also

Discover More
What is the Intrinsic Value of one DCTH stock?

The intrinsic value of one DCTH stock under the Base Case scenario is 17.26 USD.

Is DCTH stock undervalued or overvalued?

Compared to the current market price of 10.77 USD, Delcath Systems Inc is Undervalued by 38%.

Back to Top